Severity of maternal SARS-CoV-2 infection and perinatal outcomes during the Omicron variant dominant period: UK Obstetric Surveillance System national cohort study

Design, data sources and study period

A national, prospective observational cohort study was conducted using the UK Obstetric Surveillance System (UKOSS).¹² This system entails active surveillance with reporting from all 194 hospitals in the UK with a consultant-led maternity unit, and includes well established routines to secure complete reporting.¹³ Information on women who died, or who had stillbirths or neonatal deaths, was cross-checked with data from the organisation responsible for maternal and perinatal death surveillance in the UK (MBRRACE-UK).¹⁴ As individual-level SARS-CoV-2 variant data were not recorded in medical records, the data collection time period was restricted to the period in which the Omicron SARS-CoV-2 variant was the dominant circulating strain in the UK. The cut-off at December 15 was chosen since the variant then represented 50% or more of sequenced new cases from Public Health England.¹¹

Study population and study groups

Women were included if they were admitted to hospital during pregnancy and had a positive SARS-CoV-2 PCR test at the time of admission. Hospital admission was defined as an overnight or longer hospital admission for any cause, or admission of any duration to give birth. Women not meeting this case definition were excluded (Figure 1). The included women were categorised in two mutually exclusive groups based on covid-19 symptoms. Symptomatic group: women who were admitted due to covid-19 or who were reported to be symptomatic or who received respiratory support of any kind.

• Download figure
• Open in new tab

Figure 1 Inclusion flow chart:

pregnant women admitted to hospital with SARS-CoV-2 infection, by admission group, UK, 15^th December 2021 to 14^th January 2022

Asymptomatic group: women admitted for labour, obstetric care or other reasons and who were not reported to have SARS-CoV-2-related symptoms and who did not receive respiratory support, or who were reported to be asymptomatic if the reason for admission was not known.

Vaccination status was categorised as follows; unvaccinated, one dose, two doses and three doses, or vaccination status unknown.

Measures

A composite measure indicating moderate to severe SARS-CoV-2 infection was based on the WHO criteria of covid-19 disease severity.¹⁵ Women were classified as having moderate to severe respiratory disease if one or more of the following was reported: oxygen saturation <95% on admission, need for respiratory support, evidence of pneumonia on imaging, admission to ICU, or maternal death. Respiratory support was recorded as the maximum level of support in one of the following categories: oxygen therapy (supplementation on nasal prongs or non-rebreathe mask <15 l/min), high-flow nasal cannula ≥15 l/min or continuous positive airway pressure (CPAP), mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO). Mode of birth was categorised as follows; caesarean section prior to or in labour, assisted vaginal birth, unassisted vaginal birth. Gestational age was categorised by completed weeks as <22 weeks, 22 to 27 weeks, 28 to 33 weeks, 34 to 36 weeks and ≥37 weeks for gestational age at admission and gestational age at childbirth. The following perinatal outcomes were included: total births, live births, stillbirths, neonatal unit (NNU) admission, early neonatal death.

The following sociodemographic and medical risk factors were included: maternal age, body mass index (BMI) in kg/m², occupation (woman or partner in paid work vs neither in paid work), minority ethnic background (Asian, Black, Chinese, other or mixed ethnic minorities vs White), smoking (current smoker vs non-smoker), medical conditions prior to or during pregnancy (asthma, hypertension, cardiac disease, and diabetes prior to or in pregnancy), parity (nulliparous vs multiparous), plurality (singleton vs multiple).

Descriptions of pharmacological therapies were based on national guidance on pharmacological therapy issued on 01/07/2020 using the current edition at the time of admission¹⁶.

Study registration

The study was registered with ISRCTN, number 40092247 and the protocol is available at https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-pregnancy.

Role of the funding source

The funder played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Ethics and consent

This study was approved by the HRA NRES Committee East Midlands – Nottingham 1 (Ref. Number: 12/EM/0365).

Patient and Public Involvement

Patients and public were part of the UKOSS steering committee and involved in study oversight but not in the design, reporting, conduct or dissemination of this study.

Statistical methods and analysis

Continuous variables were summarised by medians with interquartile range (IQR) for non-normal distributions. Numbers and proportions are presented, and where data were missing, proportions are presented out of cases known. Statistical analyses were performed using STATA version 17 (Statacorp, TX, USA).

In this national observational study, the study sample size was governed by the disease incidence, thus no formal power calculation was carried out.

Respiratory support and medical treatment for symptomatic women

Two women (0.2%) in the asymptomatic group were admitted to ICU for indications unrelated to their SARS-CoV-2 infection. Overall, 86 (19.2%) of the symptomatic women had at least one indicator of moderate to severe infection (Table 2). However, the proportion of symptomatic women who received any specific pharmacological therapy was low (n=31, 6.9%); 0.4% (n=2) received antivirals, 1.6% (n=7) received tocilizumab, 5.8% (n=26) received corticosteroids for maternal indication, and 0.9% (n=4) received monoclonal antibodies. Four women were recruited to the RECOVERY trial. Among the 19 symptomatic women admitted to ICU, 10 (52.6%) received a specific pharmacological therapy, 1 woman (5.3%) received antivirals, 4 (21.0%) received tocilizumab, 9 (47.4%) received corticosteroids for a maternal indication and 2 (10.5%) received monoclonal antibodies.

Vaccination status

The proportion of symptomatic women who had received none, one, two or three vaccine doses was 65.1% (n=249), 11.8% (n=45), 19.8% (n=76), and 3.4% (n=13), respectively (Table 1). A total of 78 (20.4%) symptomatic women whose vaccination status was known had a composite measure of moderate to severe infection. More than a fifth of unvaccinated women (59/249, 23.7%) and women who had received one dose (10/45, 22.2%) had moderate to severe infection, compared to one in ten (9/76, 11.8%) who had two doses and none (0/13, 0%) who had three doses. Forty of the women in the two-dose group (52.6%) were known to have received their second vaccine dose more than three months prior to admission; this included five of the nine women who had a composite indicator of moderate to severe infection and the woman who was admitted to ICU. Overall, none of the women (0/68) who had a composite indicator of moderate to severe infection and known vaccination status had completed the vaccination schedule advised to protect the general adult population against severe omicron infection.

Pregnancy outcomes

One thousand, one hundred and seventy-two women had completed their pregnancies, 240 (53.5%) of the women in the symptomatic group and 932 (83.8%) in the asymptomatic group (Table 4). Almost a third of symptomatic women (n=144, 32.1%) were known to have been discharged still pregnant. The proportion of births at gestational weeks 22 to 36 was 17.8% (n=42) amongst symptomatic women versus 10.7% (n=96) in asymptomatic women. Birth expedited due to covid-19 was reported for 7.6% (n=18) in the symptomatic group; none of these women were known to have received three vaccine doses (Table 5).

Among 1159 infants, 10 stillbirths were reported; in the symptomatic and asymptomatic groups stillbirths occurred in 0.8% (n=2) and 0.9% (n=8) of total births, respectively (Table 6). Eight of the ten stillbirths occurred to women who were unvaccinated or had one vaccine dose, but the role of SARS-CoV-2 in the stillbirth needs to be assessed in formal audit. Admission to a neonatal unit was reported for 15.4% (n=37) of infants born to symptomatic women and 8.5% (n=78) of infants born to asymptomatic women.

Principal findings

This national prospective cohort study has identified that among pregnant women admitted with SARS-CoV-2 infection during the period when the Omicron VOC was dominant around one in four were symptomatic. One in seven of these symptomatic pregnant women needed respiratory support. One in four symptomatic pregnant women who had received no vaccine or a single dose had moderate to severe infection. One in eight symptomatic pregnant women who had received two doses had moderate to severe infection. No symptomatic pregnant women who had received three doses had moderate or severe infection, though the number of pregnant women admitted with symptomatic SARS-CoV-2 infection who had received three vaccine doses was very small. No women with moderate to severe respiratory disease, ICU admission or who died had received vaccines according to the recommended schedule for the general adult population for the Omicron variant.

Strengths and weaknesses of the study

To our knowledge, this is the first national prospective cohort study to describe pregnancy and perinatal outcomes during the period when the Omicron SARS-CoV-2 variant was dominant. A key strength of these data is the existing mechanism for national case identification of all women admitted to hospital across the UK, and therefore the low risk of selection bias. In the UK, universal SARS-CoV-2 testing for all obstetric admissions was implemented from May 2020. Asymptomatic pregnant women in whom SARS-CoV-2 infection is detected by screening on admission, are most commonly admitted to give birth.¹⁷ We therefore categorised the included women by cause of admission or symptoms to avoid misclassification bias and increased adverse outcomes being incorrectly attributed to SARS-CoV-2.¹⁸

Some of the pregnant women who had received two vaccine doses or fewer may also have delayed the second dose due to covid-19 infection; information about previous infection was not available in the current study. These women could potentially be misclassified into a category with lower expected protection while having reduced risk due to post-infection immunity, and this could result in overestimation of the protective effect of different vaccine doses. As with previous analyses,⁵ variant sequencing data were not available for individual women, and a proxy time period was used instead which may be considered a limitation. Additionally, more women in the symptomatic group have not completed their pregnancies, compared to the asymptomatic group, which is likely to affect the observed rates of key neonatal outcomes.

Interpretation and comparison with related studies

The proportion of symptomatic women with moderate to severe infection was lower overall than in the wildtype, Alpha and Delta variant periods in the UK^{5 13}. However, a greater proportion of symptomatic pregnant women had received one or more vaccine doses than in previous variant periods and this needs to be taken into account when comparing outcomes across variant periods, recognising that prior vaccination is likely to confer some degree of protection from both severe illness and symptomatic infection. When solely unvaccinated pregnant women admitted with symptomatic infection are considered, maternal outcomes are very similar to those observed during the initial wildtype infection period⁵. Among those in need of respiratory support, irrespective of vaccination status, the use of mechanic ventilation or ECMO was 16.1% (10/62) and thus lower than previous periods (23.5% in Alpha and 21.4% in Delta periods)⁵.

Covid-19-specific pharmacological therapies, which are now standard care for non-pregnant patients, were used infrequently, even for women that needed respiratory support. The proportion that received any pharmacological treatment for covid-19 (one or more of an antiviral, tocilizumab, maternal corticosteroids and monoclonal antibodies) was lower than in the Alpha and Delta periods, 6.9% vs 14.9% and 13.6% respectively. While this may partly reflect a lower severity of illness, it is concerning that only around half of pregnant women admitted to ICU due to covid-19 received any covid-19 specific pharmacological treatment. The RCOG recommended in June 2020 that corticosteroid therapy should be considered for all women who were clinically deteriorating due to covid-19.¹⁶ Maternal corticosteroid treatment was reported for 5.8% of symptomatic women during the Omicron period, compared to 12.7% and 12.0% during the Alpha and Delta periods, respectively. In the current study 47% of women admitted to intensive care received corticosteroids. Understanding this persisting low use of evidence-based therapies amongst severely ill pregnant and postpartum women is an increasingly urgent priority.

Few pregnant women who had received two or more doses of vaccine were admitted with symptomatic SARS-CoV-2, and none of the women with a composite indicator for moderate or severe infection had received three vaccine doses according to current recommendations to protect non-pregnant adults against severe omicron infection. Vaccination for all pregnant women regardless of risk group in the UK was recommended from 16^th April 2021, and all adults were eligible to receive vaccination from mid-June 2021.¹⁹ Vaccine coverage surveillance among women who gave birth in England up to October 2021 reported that 29.4% of the women had received two doses of vaccine and 58.2% were unvaccinated²⁰. Similarly, vaccine coverage has been low in Scotland where 32.2% of women who gave birth in October 2021 had received two doses of vaccine during pregnancy compared to 77.4% of women of reproductive age (18-44 years), and 98.1% of women admitted to the ICU were unvaccinated.⁶ Almost 68% of the women with information about vaccination status included in the current study were unvaccinated.

In the general adult population, effectiveness after the second dose declines from 60-75% three weeks after vaccination to 20% at 15 weeks and 10% after 25 weeks,²⁰ and three doses have been shown to give better protection against severe disease with the Omicron VOC in adults.²¹ The interval between the last dose and the admission was 3 months or more among half (53%) of the women who had received two doses of vaccine. The number of pregnant women who had received a third booster dose was low in our study, but no severe cases in this group indicates the importance of the third dose to protect pregnant women from both hospital admission with symptomatic covid-19 and need for respiratory support.

Disproportionate admissions due to covid-19 among pregnant women with ethnic minority backgrounds were less prominent in the current study than previously described during the wildtype period.¹³ National guidance has emphasised the importance of addressing this inequality and advised active health seeking in these groups.¹⁶ The observation time in the current study is short and the findings cannot yet reliably indicate if the smaller differences can be attributed to better communication, prevention, health care seeking strategies or previous infection. Preliminary surveillance results indicated that the Omicron VOC has a secondary attack rate of 10-13% and therefore factors that increase transmission, such as multi-occupancy housing and public-facing occupations, are important also for this variant.^22-24 Since socioeconomic deprivation is also a known independent risk factor for adverse pregnancy outcome, this could be a source of residual confounding in this study.

Neonatal outcomes were purposely not compared between omicron and other periods as a high proportion of pregnancies were continuing at the time of analysis. However, the available data suggest that the risk of stillbirth during this period may be lower than observed during the delta period⁵. Further follow-up is required to clarify the effect of infection during the Omicron dominant period on perinatal outcomes such as stillbirth.

Implications for clinicians and policymakers

The findings of this study indicate that the risk of severe respiratory failure in unvaccinated pregnant women with Omicron VOC is similar to that observed in the UK during the initial wildtype variant wave of the pandemic.¹³ While severe outcomes were less frequent in the current period compared to the previous Alpha and Delta variant dominant periods, it is important to keep in mind that the risk of hospital admission due to covid-19 was higher in the UK than in other European countries during the initial months of the pandemic,^25,26 possibly associated with early implementation of public health measures to limit viral transmission. If public health interventions could to some extent protect pregnant women during the first wave, individual protection through vaccination is now available. Our results indicate that most current cases of respiratory failure among pregnant women are preventable, yet vaccine uptake among pregnant women remains low compared to the general female population in fertile age. Continued, strong efforts to improve uptake of the vaccine during pregnancy are still needed. This is of even greater importance as infection continues to rapidly rise in both high and low-resourced settings.²⁷